A hepatitis B diagnosis requires careful staging — understanding whether your infection is acute, in the immune-tolerant phase, or actively damaging your liver determines both your clinical management and what your medical aid will fund. Here's the practical pathway.
The Honest Starting Point
Chronic hepatitis B is not on the Chronic Disease List (CDL), and it is not a named chronic Diagnosis-and-Treatment Pair in the Regulations — so ongoing antiviral treatment and monitoring are not an automatic minimum benefit. Whether your scheme funds them from risk depends on its own chronic-condition rules, so confirming your cover is the first practical step. (Acute hepatitis B with liver failure is a PMB emergency, and liver cancer, if it develops, is a PMB cancer condition — but those are separate from routine chronic management.)
The practical complexity lies in staging: not every chronic HBV carrier needs antiviral treatment immediately. Your doctor needs to assess viral load, liver inflammation, and fibrosis before deciding on treatment — and your scheme needs to see this documented before authorising chronic medication.
Step 1: Get the Full Baseline Workup
Your hepatologist or gastroenterologist (or GP in straightforward cases) needs a complete HBV staging workup to establish the diagnosis and stage the disease (confirm the specifics of cover with your scheme):
- HBsAg confirmation (confirms chronic infection if positive >6 months)
- HBeAg and anti-HBe (e-antigen status defines phase of infection)
- HBV DNA quantification (viral load — critical for treatment decision)
- Liver function tests (ALT, AST, bilirubin, albumin, GGT)
- FBC, creatinine, phosphate (baseline before starting TDF)
- Liver fibrosis assessment: FibroScan (transient elastography) — non-invasive, preferred over biopsy; measures liver stiffness as a proxy for fibrosis. Funded under procedure/radiology benefit. Alternatively: APRI or FIB-4 score from routine blood tests.
- HIV test (all HBV patients should be tested — SA context)
- Hepatitis C serology (exclude co-infection)
- Hepatitis A IgG (if HAV-naive, recommend HAV vaccination)
- Abdominal ultrasound (baseline liver morphology, check for existing cirrhosis or HCC)
Step 2: Register Your Chronic HBV With Your Scheme
Once chronic HBV is confirmed, call your scheme to register it under its chronic-condition benefit:
"I have been confirmed as chronically HBV-infected (HBsAg-positive for over 6 months, ICD-10 B18.1). I understand Hepatitis B is not a CDL condition — please tell me whether my scheme funds chronic Hepatitis B treatment and monitoring, and how to register for it. My doctor can provide a clinical motivation and blood results."
Documents to submit: - GP/specialist letter confirming chronic HBV, ICD-10 code B18.1 (chronic viral hepatitis B with delta agent, or B18.0/B18.1/B18.9 as applicable) - HBsAg positive test result - HBV DNA result - Proposed management plan (treatment or watchful waiting with surveillance)
Registration lets your scheme fund antiviral medication and monitoring where its chronic-condition rules provide for HBV. Because chronic HBV is not a CDL condition, this is not an automatic minimum-benefit entitlement — confirm the level of cover.
Step 3: Understand Whether You Need Treatment Now
Your hepatologist will determine your treatment phase:
HBeAg-positive immune-tolerant phase: Very high HBV DNA, normal ALT, minimal liver damage — many guidelines do not require immediate treatment in young patients; active surveillance instead.
Immune-active phase (HBeAg-positive or negative with elevated ALT and HBV DNA): Treatment indicated. This is when your scheme should fund antiviral therapy.
Inactive chronic hepatitis B carrier: Low HBV DNA (<2,000 IU/mL), normal ALT — watchful waiting with 6-monthly monitoring; treatment deferred.
If your doctor recommends deferring treatment, ensure active surveillance is in place — 6-monthly LFTs and HBV DNA, 6-monthly ultrasound.
Step 4: Start Tenofovir — Confirm Formulary and Scheme Cover
If treatment is indicated, first-line in SA is tenofovir disoproxil fumarate (TDF) 300mg daily.
"I have been diagnosed with chronic Hepatitis B requiring antiviral treatment. My doctor has prescribed tenofovir 300mg daily. Is this covered for my chronic Hepatitis B, and under which benefit? Please confirm the formulary code."
Generic tenofovir is widely available in SA and inexpensive (R200–R600/month). Because tenofovir is used for both HIV and hepatitis B, it is well-established in the SA formulary context.
Chronic dispensing (90-day supply): ask your pharmacist for a 3-month supply to reduce dispensing fees. Where your scheme funds chronic HBV, ask whether a chronic dispensing arrangement applies.
Step 5: Set Up HCC Surveillance — Non-Negotiable
People with chronic HBV have elevated risk of hepatocellular carcinoma (HCC) — even without cirrhosis if certain risk factors are present (Asian males, African males, family history of HCC, coexisting cirrhosis).
The standard surveillance protocol: - 6-monthly liver ultrasound - 6-monthly serum AFP (alpha-fetoprotein)
Confirm with your scheme whether these are covered and under which benefit. This surveillance is lifelong for chronic HBV patients — it is not a once-off event.
Say: "I have chronic Hepatitis B. Please confirm 6-monthly liver ultrasound and AFP are covered as monitoring for hepatocellular carcinoma surveillance, and under which benefit."
Step 6: Household and Sexual Contacts — Vaccination
HBV is highly infectious. If household members, sexual partners, or close contacts have not been vaccinated or have not had prior HBV:
- HBV vaccination: 3-dose series (0, 1, 6 months)
- Confirm immunity with anti-HBs titre after vaccination
- Vaccination is available at GPs, pharmacies, and Dis-Chem/Clicks clinics
Vaccination of contacts is a preventive service for unaffected individuals and is generally not funded from risk. Cost: R300–R600/dose (brand-dependent). Engerix-B and Heberbiovac HB are available in SA.
Key Calls to Make
| Call | What to say |
|---|---|
| Chronic registration | "Chronic HBV, ICD-10 B18.1. Does my scheme fund chronic Hepatitis B, and is tenofovir covered?" |
| HCC surveillance | "Please confirm 6-monthly liver ultrasound and AFP are covered for HCC surveillance, and under which benefit." |
| Monitoring bloods | "Please confirm LFTs and HBV DNA quantification are covered under my chronic/monitoring benefit — how often per year?" |
Talk to Eldon
Chronic hepatitis B is not a CDL condition, so cover for lifelong monitoring and antivirals varies by scheme rather than being an automatic entitlement. AURA confirms whether and how your scheme funds chronic Hepatitis B, registers it correctly, and verifies HCC surveillance is coded so it is not rejected as an elective radiology request.
Review your plan for Hepatitis B coverage →